Cascadian Therapeutics (CASC) versus Bioverativ (BIVV) Financial Analysis

Cascadian Therapeutics (NASDAQ: CASC) and Bioverativ (NASDAQ:BIVV) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, valuation and profitability.

Valuation and Earnings

How to Become a New Pot Stock Millionaire

This table compares Cascadian Therapeutics and Bioverativ’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cascadian Therapeutics N/A N/A -$56.93 million ($1.34) -7.48
Bioverativ $1.17 billion 9.72 $355.60 million $2.74 38.31

Bioverativ has higher revenue and earnings than Cascadian Therapeutics. Cascadian Therapeutics is trading at a lower price-to-earnings ratio than Bioverativ, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cascadian Therapeutics and Bioverativ’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cascadian Therapeutics N/A -43.53% -40.90%
Bioverativ 30.43% 40.99% 22.79%

Insider and Institutional Ownership

81.4% of Cascadian Therapeutics shares are held by institutional investors. Comparatively, 97.2% of Bioverativ shares are held by institutional investors. 1.1% of Cascadian Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations for Cascadian Therapeutics and Bioverativ, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cascadian Therapeutics 1 2 2 0 2.20
Bioverativ 0 12 3 0 2.20

Cascadian Therapeutics presently has a consensus target price of $7.00, suggesting a potential downside of 30.14%. Bioverativ has a consensus target price of $64.00, suggesting a potential downside of 39.04%. Given Cascadian Therapeutics’ higher possible upside, equities analysts clearly believe Cascadian Therapeutics is more favorable than Bioverativ.

Summary

Bioverativ beats Cascadian Therapeutics on 9 of the 11 factors compared between the two stocks.

Cascadian Therapeutics Company Profile

Cascadian Therapeutics, Inc., formerly Oncothyreon Inc., is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor. The Company’s ONT-10 is a therapeutic vaccine targeting the Mucin 1 peptide antigen (MUC1). The Company is engaged in developing preclinical product candidates in oncology using its Checkpoint kinase 1 (Chk1) kinase inhibitor and protocell technology. The Company completed the evaluation of approximately two dosing cohorts in its Phase Ib trial of ONT-10 in combination with the anti-CD27 T-cell agonist antibody varlilumab in collaboration with other company. The Company has completed Phase I trial of ONT-380, with both dose-escalation and expansion components. The Company has initiated Phase Ib trials of ONT-380.

Bioverativ Company Profile

Bioverativ Inc. (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively. ELOCTATE and ALPROLIX use a process known as Fc fusion to link recombinant factor VIII and factor IX, respectively, to a protein fragment in the body known as Fc. The fusion of the factor with the Fc protein fragment uses a naturally occurring pathway and is designed to extend the half-life of the factor thereby making the product last longer in a person’s blood than various factor therapies. Its pipeline includes BIVV 001(rFVIIIFc-VWF-XTEN) and BIVV 002 (rFIXFc-XTEN).

Receive News & Ratings for Cascadian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Zacks: Analysts Expect Bank Of Princeton  to Post $0.51 EPS
Zacks: Analysts Expect Bank Of Princeton to Post $0.51 EPS
Energen  Earns Buy Rating from Stephens
Energen Earns Buy Rating from Stephens
Smart Sand  Expected to Post Earnings of $0.08 Per Share
Smart Sand Expected to Post Earnings of $0.08 Per Share
JetPay  Getting Favorable News Coverage, Accern Reports
JetPay Getting Favorable News Coverage, Accern Reports
Glen Burnie Bancorp  Receives News Sentiment Rating of -0.08
Glen Burnie Bancorp Receives News Sentiment Rating of -0.08
MKS Instruments  Releases Q2 Earnings Guidance
MKS Instruments Releases Q2 Earnings Guidance


© 2006-2018 Ticker Report. Google+.